A first-in-human clinical trial – the  “THERESA” study – took place at three sites in Barcelona, Spain, under the direction of Joan Vidal-Jové, MD, PhD, Head of Focused Ultrasound Ablation Oncology at Barcelona University Hospital.

Eight enrolled patients, ages 46 to 87 years, underwent general anesthesia prior to receiving histotripsy ablation to a total of 11 liver lesions, which ranged in size from 0.5 to 2.1 cm (average 1.3 cm). All patients suffered from primary or multifocal liver metastases with the following primary tumors: colorectal cancer (5 patients), gallbladder carcinoma (1 patients), hepatocellular carcinoma (1 patient), and breast cancer (1 patient).

The Focused Ultrasound Foundation Newsletter

Our newsletter delivers updates for clinicians, researchers and patients. Sign up and stay on top of the rapid advancements of this innovative medical technology.

Sign Up  Read the Latest Issue

Read The Tumor  by John Grisham

From John Grisham, comes a story where today’s medical fiction could become tomorrow’s lifesaving reality.

Download a Free eBook or Audiobook

Contact Details

Call Us
434.220.4993
Find Us
Focused Ultrasound Foundation
1230 Cedars Court, Suite 206 Charlottesville, VA 22903
Email